Efficacy and safety of Naoxintong capsule for secondary prevention after reperfused acute myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial.
PhytomedicineJul 15, 2026 (epub)
Clinical ResearchCardiology
Haitong Wan, Sina Liu, Shenglei Qiu et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Naoxintong (NXT) in 379 patients post-reperfusion for acute myocardial infarction (AMI). NXT significantly reduced the incidence of new-onset heart failure (5.98% vs. 14.06%; HR 0.41, p = 0.01) and major adverse cardiovascular events (7.97% vs. 14.84%; HR 0.52, p = 0.04) compared to placebo over 12 months.
Key findings
- NXT reduced new-onset heart failure incidence to 5.98% compared to 14.06% in the placebo group.
- The incidence of major adverse cardiovascular events was 7.97% in the NXT group versus 14.84% in the placebo group.
- Serious adverse events occurred in 7.97% of the NXT group compared to 14.84% in the placebo group.
- Any adverse events were lower in the NXT group at 7.97% versus 21.09% in the placebo group.
Why it matters
The findings suggest that Naoxintong may serve as an effective complementary treatment for reducing heart failure and major adverse cardiovascular events in patients recovering from acute myocardial infarction, potentially improving long-term outcomes.